Heron Therapeutics, Inc. /De/: Pay

Heron Therapeutics, Inc. /De/ paid its 4 named executives $11.1M in total in FY2025 (Dec). CEO Craig Collard was paid $3.5M of that.

Pay$100 in the stock at the end of FY21 → $14
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Mark HensleyEVP, Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
3 years
Craig CollardChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
William ForbesEVP, Chief Development Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Ira DuarteEVP, Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $4.5M. The CEO of Heron Therapeutics, Inc. /De/ was paid $3.5M, 22% below the median.

  1. 1Travere Therapeutics
  2. 2Innoviva
  3. 3Rigel Pharmaceuticals
  4. 4UroGen Pharma
  5. 5Vanda Pharmaceuticals
  6. 6Lexicon Pharmaceuticals
  7. 7Heron Therapeutics, Inc. /De/
  8. 8Ani PharmaceuticalsNot disclosed
  9. 9Akebia TherapeuticsNot disclosed
  10. 10Coherus BioSciencesNot disclosed
  11. 11Collegium PharmaceuticalsNot disclosed
  12. 12Esperion TherapeuticsNot disclosed
  13. 13G1 TherapeuticsNot disclosed
  14. 14HarrowNot disclosed
  15. 15Ocular TherapeuticsNot disclosed
  16. 16OptiNoseNot disclosed
  17. 17Phantom PharmaceuticalsNot disclosed
  18. 18Sage TherapeuticsNot disclosed
  19. 19Xeris Biopharma HoldingsNot disclosed
  20. 20Y-mAbs TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.